Update from the 5th edition of the world health organization classification of head and neck tumors: overview of the 2022 WHO classification of head and neck …
O Mete, BM Wenig - Head and neck pathology, 2022 - Springer
This review article provides a brief overview of the new WHO classification by adopting a
question–answer model to highlight the spectrum of head and neck neuroendocrine …
question–answer model to highlight the spectrum of head and neck neuroendocrine …
Non-melanoma skin cancers: Biological and clinical features
M Cives, F Mannavola, L Lospalluti, MC Sergi… - International Journal of …, 2020 - mdpi.com
Non-melanoma skin cancers (NMSCs) include basal cell carcinoma (BCC), squamous cell
carcinoma (SCC) and Merkel cell carcinoma (MCC). These neoplasms are highly diverse in …
carcinoma (SCC) and Merkel cell carcinoma (MCC). These neoplasms are highly diverse in …
Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
Background Merkel cell carcinoma is among the most aggressive and lethal of primary skin
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …
cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD …
[HTML][HTML] Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN …
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
[HTML][HTML] Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor
survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
[PDF][PDF] Progress and challenges of predictive biomarkers for immune checkpoint blockade
Y Lei, X Li, Q Huang, X Zheng, M Liu - Frontiers in Oncology, 2021 - frontiersin.org
Over the past decade, immune checkpoint blockade (ICB) therapy has revolutionized the
outlook for oncology with significant and sustained improvement in the overall patient …
outlook for oncology with significant and sustained improvement in the overall patient …
Molecular pathogenesis of Merkel cell carcinoma
JA DeCaprio - Annual Review of Pathology: Mechanisms of …, 2021 - annualreviews.org
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin with
two distinct etiologies. Clonal integration of Merkel cell polyomavirus DNA into the tumor …
two distinct etiologies. Clonal integration of Merkel cell polyomavirus DNA into the tumor …
Merkel cell carcinoma: A review
NM Walsh, L Cerroni - Journal of Cutaneous Pathology, 2021 - Wiley Online Library
Merkel cell carcinoma has been a focus of active scientific investigation in recent years and
new information on the topic has emerged. Although uncommon, this primary cutaneous …
new information on the topic has emerged. Although uncommon, this primary cutaneous …
Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal
survival outcomes. A major barrier in the field has been the relative paucity of human tumors …
survival outcomes. A major barrier in the field has been the relative paucity of human tumors …